KRAS and colorectal carcinoma: The percentage of CRC patients with more than 3 CTCs/7.5 ml of blood at basal blood draw was consistent, albeit slightly lower, with that reported in the literature6–8 for samples not selected for the presence of KRAS mutations processed with the same method.